Vitalograph
Vitalograph is recorded as a service provider in 24 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 24 trials · Latest update first
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
Sponsor Scleroderma Research Foundation
- Start (EU)
- Latest update
- Estimated end
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants with Refractory Chronic Cough
Sponsor Trevi Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)
Sponsor Prometheus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)
Sponsor Cartesian Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
Sponsor Bellus Health Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects with Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease
Sponsor Genentech Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years with Late-onset Pompe Disease
Sponsor Amicus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)
Sponsor Avalyn Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)
Sponsor Bellus Health Inc.
- Start (EU)
- Latest update
- Estimated end
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
An Open Label Follow-Up Study to Evaluate the Long Term Safety and Efficacy of L-CSA in Patients with a Diagnosis of CLAD-BOS after they have completed the participation to BOSTON 1 and BOSTON 2 studies
Sponsor Zambon S.p.A.
- Start (EU)
- Latest update
- Estimated end
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 pMDI 200/6/12.5 µg HFA-152a, compared to CHF5993 pMDI 200/6/12.5 µg HFA-134a, in subjects with asthma
Sponsor Chiesi Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Trevi Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients with Inflammatory Lung Disease
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Vitalograph?
The 2026-10-09 snapshot links Vitalograph to 24 distinct CTIS trials. Recorded services include Cardiac services, Measurement of recorded cough frequency, Spirometry Central Reading and Blood Pressure Reading, Equipment Rental Services, Cardio-respiratory vendor ( i.e., ECGs, FVC, MIP and MEP testing), among 20 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Vitalograph?
The most frequently recorded therapeutic areas are Respiratory, Immunology, Rheumatology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Vitalograph conducted?
The linked trials record locations in 21 countries, including Spain, Poland, Germany, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Vitalograph delivered services.
What can this page tell me about Vitalograph's trial experience?
Browse 24 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Vitalograph. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Vitalograph
- Vitalograph Inc.
- Vitalograph Limited